Search

CN-121971506-A - Exosome composition containing resveratrol-astragalus membranaceus-ginseng as well as preparation method and application thereof

CN121971506ACN 121971506 ACN121971506 ACN 121971506ACN-121971506-A

Abstract

The invention discloses an exosome composition containing resveratrol-astragalus membranaceus-ginseng and a preparation method and application thereof, and belongs to the technical field of biological medicines. The exosome composition is obtained by inducing alveolar epithelial cells by active ingredients comprising resveratrol, astragalus extract and ginseng extract. The preparation method of the exosome composition mainly comprises the steps of co-culturing the active ingredient and alveolar epithelial cells, and then sequentially performing differential centrifugation and ultracentrifugation on the collected cell supernatant to purify the exosome. The invention also provides a pharmaceutical formulation comprising the exosome composition. The composition provides a potential strategy for preventing and treating pulmonary fibrosis by combining the active ingredients of the traditional Chinese medicine with the modern exosome technology, and has a good application prospect.

Inventors

  • YANG XIAOCHEN

Assignees

  • 北京圣美细胞生命科学工程研究院有限公司

Dates

Publication Date
20260505
Application Date
20260225

Claims (10)

  1. 1. An exosome composition for preventing and/or treating pulmonary fibrosis, wherein the exosome composition is secreted by alveolar epithelial cells after induction of an active ingredient comprising resveratrol, astragalus extract and ginseng extract.
  2. 2. The exosome composition of claim 1, wherein the alveolar epithelial cells are human alveolar epithelial cell lines or primary alveolar epithelial cells.
  3. 3. The exosome composition according to claim 1, wherein the mass ratio of resveratrol, astragalus extract, and ginseng extract is (1-5): 10-30.
  4. 4. A process for the preparation of an exosome composition for preventing and/or treating pulmonary fibrosis, the process comprising the steps of: Adding resveratrol, radix astragali extract and Ginseng radix extract into alveolar epithelial cell culture medium, co-culturing, and collecting cell supernatant; and (3) carrying out differential centrifugation on the cell supernatant to collect supernatant, and carrying out ultracentrifugation on the supernatant to collect precipitate to obtain the exosome composition.
  5. 5. The method according to claim 4, wherein the conditions for differential centrifugation include centrifugation at 500 Xg for 10-20 minutes, centrifugation at 2000 Xg for 20-30 minutes, and centrifugation at 10000 Xg for 25-35 minutes at 4 ℃.
  6. 6. The method according to claim 4, wherein the ultracentrifugation is performed at a centrifugal force of 100000 Xg for 80 to 100 minutes at 4 ℃.
  7. 7. The method according to claim 4, wherein the co-cultivation is carried out for 24 to 72 hours.
  8. 8. The preparation method according to claim 4, wherein the final concentration of the active ingredient in the culture medium is 1-50. Mu.M resveratrol, 10-200. Mu.g/mL of radix astragali extract, and 10-200. Mu.g/mL of ginseng extract, respectively.
  9. 9. A pharmaceutical formulation comprising the exosome composition of any one of claims 1-3 and a pharmaceutically acceptable carrier.
  10. 10. Use of an exosome composition according to any one of claims 1-3, an exosome composition prepared by a method according to any one of claims 4-8, or a pharmaceutical formulation according to claim 9 in the manufacture of a medicament for the prevention and/or treatment of pulmonary fibrosis.

Description

Exosome composition containing resveratrol-astragalus membranaceus-ginseng as well as preparation method and application thereof Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to an exosome composition containing resveratrol-astragalus membranaceus-ginseng, and a preparation method and application thereof. Background Pulmonary fibrosis (Pulmonary Fibrosis) is a chronic, progressive, lethal interstitial lung disease characterized by excessive deposition of extracellular matrix in the lung interstitium, progressive destruction of alveolar structure, and irreversible loss of lung function. Its etiology is complex, including idiopathic, environmental exposure, drug toxicity, autoimmune disease secondary and so on types, with Idiopathic Pulmonary Fibrosis (IPF) with poor prognosis. At present, clinical standard treatment drugs such as pirfenidone and nidanib mainly delay disease progression by inhibiting fibroblast proliferation and collagen synthesis, but have obvious side effects of limited curative effect, large individual difference, gastrointestinal tract and liver injury and the like, and cannot reverse formed fibrosis, so that a patient needs a safer and more effective novel treatment strategy. The traditional Chinese medicine shows the unique advantages of multicomponent, multi-target and overall regulation in the aspect of preventing and treating pulmonary fibrosis. A large number of researches show that astragalus has the effects of tonifying qi, consolidating exterior and regulating immunity, the active ingredient astragaloside IV can inhibit the signal path of transforming growth factor beta 1 (TGF-beta 1), ginseng can strengthen primordial qi greatly, strengthen body resistance and consolidate constitution, ginsenoside Rg1, rb1 and the like have the effects of resisting inflammation and oxidative stress, resveratrol is taken as natural polyphenol, and is widely researched by virtue of strong anti-inflammatory, antioxidant and anti-fibrosis activities. However, the active ingredients have low oral bioavailability, rapid in vivo metabolism, lack of targeting to diseased lung tissues, and difficulty in achieving effective therapeutic concentration in lesions due to systemic administration, so that the full play of clinical effects is limited. In recent years, extracellular vesicles, particularly Exosomes (Exosomes), have received great attention as a drug delivery system in the field of disease treatment. Exosomes are lipid bilayer vesicles with diameters of about 30-150 nanometers actively secreted by cells, naturally bear bioactive substances such as proteins, nucleic acids (such as miRNAs and mRNAs) and lipids of source cells, and have low immunogenicity, good biocompatibility and capability of crossing biological barriers. Research shows that exosomes derived from mesenchymal stem cells can regulate and control target cell functions by delivering anti-fibrosis miRNAs (such as miR-29 and miR-let-7 d), and have certain therapeutic potential in a pulmonary fibrosis animal model. However, the function of exosomes is highly dependent on their cell origin and culture conditions. At present, the production of therapeutic exosomes is concentrated on stem cells, the culture and expansion cost is high, the uniformity is difficult to control, the inherent biological functions are relatively fixed, and the directional transformation or the functional enhancement is difficult to carry out according to the therapeutic requirements. At present, a scheme for efficiently combining the synergistic advantage of traditional Chinese medicine components with the existing exosome targeted delivery technology and directionally optimizing the exosome treatment function by carrying out specific pretreatment on secretory cells is not available. Specifically, how to use a definite combination of active ingredients of traditional Chinese medicines to induce functional cells closely related to pulmonary diseases to secrete a novel exosome composition which has both the action of the active ingredients of the traditional Chinese medicines and the natural targeting function of exosomes and has synergistically enhanced anti-fibrosis effect is still a technical problem to be solved. Disclosure of Invention Accordingly, the present invention aims to provide an exosome composition for preventing and/or treating pulmonary fibrosis, which is capable of efficiently loading resveratrol, astragalus extract and ginseng extract into an exosome derived from alveolar epithelial cells with natural targeting, thereby providing a novel strategy for treating pulmonary fibrosis with better therapeutic effect and less potential side effects. In order to achieve the above object, the present invention provides the following technical solutions: the present invention also provides an exosome composition for preventing and/or treating pulmonary fibrosis, which is secreted from alveolar ep